Coronavirus (CoVID-19) is a new outbreak of coronavirus disease which started in the Wuhan, China, the spread of this virus has now reached a global stage, urgent need is therefore needed to find new drug molecules which can either be used as a first aid intervention or slow down the multiplication rate of the virus within the system. In order to address this, this research looked into the existing antiviral drugs and screened them for their inhibitory properties towards the CoVID-19 protein. Recently, the crystal structure of the CoVID-19 (6LU7) protein has been established, this gives us the possible drug target site in CoVID-19. The binding affinity of the six compounds was screened using MOE (Molecular Operating Environment) software, four compounds (Zanamivir, Peramivir, Rimantidine, and Oseltamivir) out these six compounds have been approved by the Food Drug and Administration (FDA). The molecular docking calculation, Higher Occupied Molecular Orbital (HOMO) and Lowest Unoccupied Molecular Orbital (LUMO) calculation were used to hypothesise the bioactivity of the FDA approved drug against the CoVID-19 protein. The calculation showed that Pimodivir tops the list of the anti influenza drug which can be used as first aid treatment for patient. Apart from Pimodivir, Laninamivir Octanoate is also a very good drug which might be used to inhibit CoVID-19 protein. It was also discovered that based on binding property of Rimantadine, it might be suitable for Fragment Based Drug Design (FBDD) approach which might lead to the discovery of completely new drug entity. Stability of the new protein structure was studied using GROMACS molecular dynamic simulation software. The results showed that the stability of the protein structure was achieved over a range of time, this confirmed that 6LU7 crystal structure might be a suitable protein crystal structure suitable for the development of new drug towards the treatment of CoVID-19. Finally, based on the molecular docking result, Pimodivir and Laninamivir Octanoate might be useful in the treatment of infected patient.
References
[1]
Korsman, S.N.J. and Preiser, W. (2012) Virology. In: Human Coronaviruses, Churchill Livingstone, New York, 94-95. https://doi.org/10.1016/B978-0-443-07367-0.00040-9
[2]
Greenberg, D.P., Walker, R.E., Lee, M.S., Reisinger, K.S., Ward, J.I., Yogev, R., Blatter, M.M., Yeh, S.H., Karron, R.A., Sangli, C., Eubank, L., Coelingh, K.L., Cordova, J.M., August, M.J., Mehta, H.B., Chen, W. and Mendelman, P.M., (2005) A Bovine Parainfluenza Virus Type 3 Vaccine Is Safe and Immunogenic in Early Infancy. The Journal of Infectious Diseases, 191, 1116-1122. https://doi.org/10.1086/428092
Tortorici, M.A., Walls, A.C., Lang, Y.F., Wang, C.Y., Li, Z.S., Koerhuis, D., Boons, G.-J., Bosch, B.-J., Rey, F.A., de Groot, R.J. and Veesler, D. (2015) Structural Basis for Human Coronavirus Attachment to Sialic Acid Receptors. Nature Structural & Molecular Biology, 26, 481-489. https://doi.org/10.1038/s41594-019-0233-y
[5]
Fehr, A.R. and Perlman, S. (2015) Coronaviruses: An Overview of Their Replication and Pathogenesis. Methods in Molecular Biology, 1282, 1-23. https://doi.org/10.1007/978-1-4939-2438-7_1
[6]
Bosch, B.J., van der Zee, R., de Haan, C.A. and Rottier, P.J. (2003) The Coronavirus Spike Protein Is a Class I Virus Fusion Protein: Structural and Functional Characterization of the Fusion Core Complex. Journal of Virology, 77, 8801-8811. https://doi.org/10.1128/JVI.77.16.8801-8811.2003
[7]
Nieto-Torres, J.L., Dediego, M.L., Verdia-Baguena, C., Jimenez-Guardeno, J.M., Regla-Nava, J.A., Fernandez-Delgado, R., Castano-Rodriguez, C., Alcaraz, A., Torres, J., Aguilella, V.M. and Enjuanes, L. (2014) Severe Acute Respiratory Syndrome Coronavirus Envelope Protein Ion Channel Activity Promotes Virus Fitness and Pathogenesis. PLoS Pathogens, 10, Article ID: 1004077. https://doi.org/10.1371/journal.ppat.1004077
[8]
Belouzard, S., Chu, V.C. and Whittaker, G.R. (2009) Activation of the SARS Coronavirus Spike Protein via Sequential Proteolytic Cleavage at Two Distinct Sites. Proceedings of the National Academy of Sciences of the United States of America, 106, 5871-5876. https://doi.org/10.1073/pnas.0809524106
[9]
Baranov, P.V., Henderson, C.M., Anderson, C.B., Gesteland, R.F., Atkins, J.F. and Howard, M.T. (2005) Programmed Ribosomal Frame Shifting in Decoding the SARS-CoV Genome. Virology, 332, 498-510. https://doi.org/10.1016/j.virol.2004.11.038
[10]
Brierley, I., Digard, P. and Inglis, S.C. (1989) Characterization of an Efficient Coronavirus Ribosomal Frameshifting Signal: Requirement for an RNA Pseudoknot. Cell, 57, 537-547. https://doi.org/10.1016/0092-8674(89)90124-4
[11]
Araki, K., Gangappa, S., Dillehay, D.L., Rouse, B.T., Larsen, C.P. and Ahmed, R. (2010) Pathogenic Virus-Specific T Cells Cause Disease during Treatment with the Calcineurin Inhibitor FK506: Implications for Transplantation. Journal of Experimental Medicine, 207, 2355-2367. https://doi.org/10.1084/jem.20100124
[12]
Ziebuhr, J., Snijder, E.J. and Gorbalenya, A.E. (2000) Virus-Encoded Proteinases and Proteolytic Processing in the Nidovirales. Journal of General Virology, 81, 853-879. https://doi.org/10.1099/0022-1317-81-4-853
[13]
Sawicki, S.G., Sawicki, D.L. and Siddell, S.G. (2007) A Contemporary View of Coronavirus Transcription. Journal of Virology, 81, 20-29. https://doi.org/10.1128/JVI.01358-06
[14]
Bentley, K., Keep, S.M., Armesto, M. and Britton, P. (2013) Identification of a Noncanonically Transcribed Subgenomic mRNA of Infectious Bronchitis Virus and Other Gamma Coronaviruses. Journal of Virology, 87, 2128-2136. https://doi.org/10.1128/JVI.02967-12
[15]
Fischer, F., Stegen, C.F., Masters, P.S. and Samsonoff, W.A. (1998) Analysis of Constructed E Gene Mutants of Mouse Hepatitis Virus Confirms a Pivotal Role for E Protein in Coronavirus Assembly. Journal of Virology, 72, 7885-7894. https://doi.org/10.1128/JVI.72.10.7885-7894.1998
[16]
Boscarino, J.A., Logan, H.L., Lacny, J.J. and Gallagher, T.M. (2008) Envelope Protein Palmitoylations Are Crucial for Murine Coronavirus Assembly. Journal of Virology, 82, 2989-2999. https://doi.org/10.1128/JVI.01906-07
[17]
Zhong, Y.X., Tan, Y.W. and Liu, D.X. (2012) Recent Progress in Studies of Arterivirus-and Coronavirus-Host Interactions. Viruses, 4, 980-1010. https://doi.org/10.3390/v4060980
[18]
Weiss, S.R. and Navas-Martin, S. (2005) Coronavirus Pathogenesis and the Emerging Pathogen Severe Acute Respiratory Syndrome Coronavirus. Microbiology and Molecular Biology Review, 69, 635-664. https://doi.org/10.1128/MMBR.69.4.635-664.2005
[19]
Andersen, P.I., Ianevski, A., Lysvand, H., Vitkauskiene, A., Oksenych, V., Bjøras, M., Telling, K., Lutsar, I., Dampis, U., Irie, Y., Tenson, T., Kantele, A. and Kainov, D.E. (2020) Discovery and Development of Safe-in-Man Broad-Spectrum Antiviral Agents. International Journal of Infectious Diseases. https://doi.org/10.20944/preprints201910.0144.v4
[20]
Liu, X., Zhang, B., Jin, Z., Yang, H. and Rao, Z. (2020) The Crystal Structure of COVID-19 Main Protease in Complex with an Inhibitor N3. https://doi.org/10.2210/pdb6lu7/pdb
[21]
Mair, C.M., Meyer, T., Schneider, K., Huang, Q., Veit, M. and Herrmann, A. (2014) A Histidine Residue of the Influenza Virus Hemagglutinin Controls the pH Dependence of the Conformational Change Mediating Membrane Fusion. Journal of Virology, 88, 13189-13200. https://doi.org/10.1128/JVI.01704-14
[22]
Haghdadi, M., Kenary, F.S. and Basra, H.G. (2014) Structure-Activity-Relationships Study of 2-Thienyl-4-Furyl-6-Aryl Pyridine Skeleton as Anti-Cancer Drugs by DFT Method. Organic Chemistry: An Indian Journal, 10, 371-376.
[23]
Marquez, E., Moira, J.R., Flores-Morales, V., Insuasty, D. and Calle, L. (2020) Modelling the Antileukemia Activity of Ellipticine-Related Compounds: QSAR and Molecular Docking Study. Molecules, 25, 24. https://doi.org/10.3390/molecules25010024
